跳至主要内容
临床试验/NCT07843264
NCT07843264尚未招募4 期

A Pilot Study to Assess Healing of Erosive Esophagitis in Patients Randomized to Conventional PPI Doses Versus Dosing Based on CYP2C19 Genotype

University of Florida0 个研究点目标入组 200 人开始时间: 2026年10月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
尚未招募
入组人数
200
主要终点
Improvement of Los Angeles (LA) classification of Erosive Esphagitis (EE) grade

研究概览

简要总结

This study is being done to determine if the dosing of proton pump inhibitor (PPI) medication based on CYP2C19 genotype-derived phenotype leads to improved healing of erosive esophagitis compared to conventional PPI medication dosing.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •age ≥ 18 years
  • •diagnosis of Gastroesophageal Reflux Disease (GERD) scheduled for an esophagogastroduodenoscopy (EGD)
  • •patients diagnosed with Erosive Esophagitis on endoscopy (EGD).

排除标准

  • •age <18 years
  • •diagnosed with non-erosive reflux disease (NERD)
  • •pregnancy

研究组 & 干预措施

Intervention

Experimental

proton pump inhibitor dose based on CYP2C19 phenotypes

干预措施: CYP2C19 based dosing Proton Pump Inhibitors (Drug)

Control

Active Comparator

conventional proton pump inhibitor dose of Pantoprazole 40 mg once or twice daily

干预措施: Conventional proton pump inhibitor dose (Drug)

结局指标

主要结局

Improvement of Los Angeles (LA) classification of Erosive Esphagitis (EE) grade

时间窗: 8 weeks

Assessment of erosive esophagitis grade to determine healing in both arms. Healing would be measured by endoscopic regression of errosive esophagitis (EE) to a lower degree of inflammation. Previously assigned baseline numerical values per the LA classification of EE will be used to calculate the degree of healing in each arm at the 8th week follow up, e.g. LA grade D (initial EGD) to LA grade A (repeat EGD) would yield a score of 3 (LA D \[5\] - LA A \[2\]). A higher score hence indicating superior healing of EE.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

相似试验